Phase II and Phase III attrition rates 2011–2012

Arrowsmith, John, Miller, Philip·2013·Nature Reviews Drug Discovery
DOI 10.1038/nrd4090

Cited by (697)

Items 601–697 of 697

  1. Sleep and Sleep Disruption
    Joanne Stevens, Carrie G. Markgraf · 2018 · Elsevier eBooks
  2. The (In)Direct Relationship Between Science & Product Commercialization in the Pharmaceutical Industry
    P. Anckaert · 2018
  3. Waar blijven de nieuwe psychofarmaca?
    Berend Olivier · 2019 · Neuropraxis
  4. Safety, Efficacy, and Regulation of Mesenchymal Stromal/Stem Cells
    Mimmi Patrikoski, Kristiina M Rajala, Susanna Miettinen · 2019 · Springer eBooks
  5. Etablierung einer Living Biobank: Bessere Steuerung der Präzisionsonkologie durch In-vitro- und In-vivo-Krebsmodelle
    Chantal Pauli, Holger Moch, Mark A. Rubin · 2017 · Der Pathologe
  6. Across the great divide
    Michael G. Collis · 2013 · Physiology News
  7. The road to IUPS
    David A. Eisner, Bridget M. Lumb · 2013 · Physiology News
  8. Statins and implications for fetal brain sparing during hypoxia
    Andrew D. Kane, Emilio A. Herrera, Avnesh S. Thakor · 2013 · Physiology News
  9. Q&A: Placements in industry
    Rebecca M. Wadey, Devon Shannon · 2013 · Physiology News
  10. Obituary: Bob Edwards (1925 – 2013)
    Martin Johnson · 2013 · Physiology News
  11. Collaborations in industry
    Stuart Wynn Hughes, Mark O. Cunningham · 2013 · Physiology News
  12. Obituary: Joseph Davison (1942 – 2013)
    L. Ashley Blackshaw, David Grundy, Keith Sharkey · 2013 · Physiology News
  13. Meeting Notes: International Early-Career Symposium (IECS)
    Emma Thompson · 2013 · Physiology News
  14. Winning a Rob Clarke Abstract Award
    Amy Rose Sharkey · 2013 · Physiology News
  15. Book review - The Sodium Theory Revisited (or 45 years as a full time CNRS neurophysiologist) By Yves Pichon
    David Miller · 2013 · Physiology News
  16. Meeting Notes: IUPS and ADInstruments Teaching Workshop
    Penny Hansen · 2013 · Physiology News
  17. Member profile
    Siobhan H. Dennis · 2013 · Physiology News
  18. Impressions of IUPS 2013
    Bryn Savill · 2013 · Physiology News
  19. Women in Science at IUPS 2013
    Caroline Wood · 2013 · Physiology News
  20. The Society’s Education and Teaching (ET) Theme: What is it and what does it do?
    Judy Harris · 2013 · Physiology News
  21. Holistic Assessment of Compound Properties—In Vitro to In Vivo Pharmacology
    Andrew Baxter · 2021 · Elsevier eBooks
  22. Studies on Prediction Systems for Revealing Biological Functions of Drug Candidates
    保則 福田, Yasunori Fukuda · 2019 · Terrestrial Environment Research Center (University of Tsukuba)
  23. Induced pluripotent stem cells for modeling of cardiac arrhythmias
    Zeina Reda Al Sayed, Marzia Corli, Nihar D. Masurkar, Jean‐Sébastien Hulot · 2021 · Elsevier eBooks
  24. Physicochemical and Biopharmaceutical Factors Affecting Hepatic/Intestinal First‐Pass Effect
    Ayman F. El‐Kattan · 2017
  25. Identifying active ingredients in cognitive-behavioral therapies: What if we didn't?
    Lorenzo Lorenzo‐Luaces · 2022
  26. Combinations of Drug Candidate Properties Affecting Development Success and Discontinuation for 5 Diseases: Lymphoma, Non–Small Cell Lung Cancer, Arthritis, Depression, and Alzheimer Disease
    Shingo Yamaguchi, Mamoru Narukawa · 2022 · The Journal of Clinical Pharmacology
  27. AbstractsIn Vitro Toxicology Society Annual Meeting10–11 November 2014AstraZeneca, Alderley ParkMacclesfield, United Kingdom
    2015 · Applied In Vitro Toxicology
  28. Regulatory Aspects
    Beatriz Silva Lima · 2014 · Methods and principles in medicinal chemistry
  29. Annual General Meeting 2013
    2013 · Physiology News
  30. Policy Corner
    2013 · Physiology News
  31. Physiology meets the public at IUPS
    2013 · Physiology News
  32. Second Dimension
    E. Andrew Balas · 2018
  33. Membership Survey 2013
    2013 · Physiology News
  34. Editorial
    Siobhan H. Dennis · 2013 · Physiology News
  35. CSL-Tox: An open-source analytical framework for the comparison of short-term and long-term toxicity end points and exploring the opportunities for decreasing in-vivo studies conducted for drug development programs
    Doha Naga, Smaragda Dimitrakopoulou, Sonia Roberts, Elisabeth Husar, Susanne Mohr, Helen S. Booler, Eunice Musvasva · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  36. Drug approval prediction based on the discrepancy between gene perturbation effects in cells and humans
    Sanguk Kim, Minhyuk Park, Donghyo Kim, Inhae Kim, Sin‐Hyeog Im · 2022 · Research Square
  37. Accelerated Weight Histogram method to assess membrane permeability
    Mehdi Benmameri, Benjamin Chantemargue, Antoine Humeau · 2022 · ChemRxiv
  38. In vitro in vivo extrapolation (IVIVE) in safety pharmacology to improve human predictability —new evaluation systems for new drug modalities—
    Daiju Yamazaki, Kaoru Sato · 2022 · Folia Pharmacologica Japonica
  39. Post-Approval Research in Drug Development: Priorities and Practices
    David Williamson, Jack Sheehan, Ella Daly · 2023 · Advances in neurobiology
  40. Drug testing: translating a novel immunotherapeutic from bench to bedside
    Kirit Singh, John Howard Sampson, Patrick C. Gedeon · 2023 · Translational Surgery
  41. Development of novel, simple and low–cost microfluidic platform for supporting 3D dynamic cell culture
    Nguyen Thanh Duong Nguyen, Thu Uyen Pham, Tran Dinh Thiet · 2023 · Vietnam Journal of Science and Technology/Science and Technology
  42. Model-based assessment of combination therapies – ranking of radiosensitizing agents in oncology
    Marcus Baaz, Tim Cardilin, Floriane Lignet, Astrid Zimmermann, Samer El Bawab, Johan Gabrielsson, Mats Jirstrand · 2023 · BMC Cancer
  43. Animal Models of Lymphoid Malignancies
    Anjali Mishra · 2023
  44. Modeling a Liver-Stage Malaria
    Kasem Kulkeaw · 2023 · Springer eBooks
  45. Introduction to Malaria Biology in a Liver
    Kasem Kulkeaw · 2023 · Springer eBooks
  46. iMOUSE - Reforming the Strategy of Refinement and Reduction for indispensable laboratory animal-based studies in translational research
    M.-A. Du Laz, Mirko Lampe, Isaac Connor, Dmytro Shestachuk, Marcel Ludwig, Ursula Müller, Oliver F. Strauch, Nadine Suendermann, Stefan Lüth, Janine Kah · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  47. Insight into the degradation of amino substituted benzimidazo[1,2-a]quinolines via a combined experimental and density functional theory study
    Kristina Tolić Čop, Nataša Perin, Marijana Hranjec · 2023 · Journal of Pharmaceutical and Biomedical Analysis
  48. Determinants of R&D Project Abandonment: Evidence from the Pharmaceutical Industry
    Ute Laermann-Nguyen · 2023 · SSRN Electronic Journal
  49. Avaliação do uso de modelos murinos BALB/c para estudos de cicatrização de lesões de pele induzidas
    Ray Silva · 2024
  50. Traditional and 3D Stem Cell Cultures Maintained in Xenobiotic-Free Conditions: Immunological Aspects
    Marna Eliana Sakalem, H Brand, Natalia Cristine Dias dos Santos, Rafael Guilen de Oliveira · 2024 · Elsevier eBooks
  51. Development of improved drug-target profiling methods using mass spectrometry-based thermal stability assays
    Clifford G. Phaneuf · 2023
  52. Exploring novel therapeutic opportunities for hypertension: a paradigm-shifting approach via integrative multiomic analysis, pioneering the path to precision medicine
    Sushant Saluja, Rachel Lennon · 2024 · Journal of Hypertension
  53. Minimizing biological risk for novel inhibitory drug targets: One knockout is all you need
    Alan Dimitriev, Lynne-Marie M Postovit, Amber L. Simpson, Gane Ka‐Shu Wong · 2024 · medRxiv
  54. Proceedings from the First Onco Summit: LATAM Chapter, 19–20 May 2023, Rio de Janeiro, Brazil
    Vânia Hungria, Anna Maria Sureda, Garcia Campelo, Marco Aurélio Salvino, Karthik Ramasamy · 2024 · Cancers
  55. Analyzing the distribution of progression-free survival for combination therapies: A study of model-based translational predictive methods in oncology
    Marcus Baaz, Tim Cardilin, Mats Jirstrand · 2024 · European Journal of Pharmaceutical Sciences
  56. Humanized mouse models in immuno-oncology
    Shuang Li, Quan Wang · 2024 · Elsevier eBooks
  57. In Vitro and In Vivo Metabolism Studies
    Biplab Das, Chandra Prakash · 2024 · Springer eBooks
  58. Failing fast in new pharmaceutical drug development
    Richard Kraude, S. K. Talluri, Sriram Narayanan, G. Tomas M. Hult · 2025 · Elsevier eBooks
  59. PKPD modeling and in silico models
    Rikard Pehrson, Susanne Winiwarter, Vigneshwari Subramanian, Mickael Mogemark, Filip N. Miljković · 2025 · Elsevier eBooks
  60. In Situ Proinflammatory Effects of Dazostinag Alone or with Chemotherapy on the Tumor Microenvironment of Patients with Head and Neck Squamous Cell Carcinoma
    Richard C. Gregory, Neil B. Lineberry, Alexander Parent, Karthik Rajasekaran, Thomas Julian Ow, Cherie‐Ann O. Nathan, Beryl A. Hatton, Wendy M. Jenkins, Marc O. Grenley, Connor Burns et al. · 2025 · Cancer Research Communications
  61. Clinical trials in otology and neurotology: state of the science
    Lindsay S. Moore, Varun Sagi, Konstantina M. Stanković · 2025 · Frontiers in Neurology
  62. Cystobactamid off-target profiling reveals favorable safety, superoxide reduction, and SCARB1 inhibition in eukaryotes
    Timo Risch, Benedikt Hellwinkel, Dietrich Mostert et al. · 2025 · npj Drug Discovery.
  63. A novel translational in-silico indication discovery framework identifies indications and predictive biomarkers for cenerimod
    Dominik Hartl, Madeleine Suffiotti, Peter Cornelisse, Daniel S. Strasser · 2025 · Research Square
  64. Rat and dog quad-culture liver chip models: characterization and use to interrogate a potential flavin-containing monooxygenase-mediated, species-specific toxicity of a histamine receptor antagonist
    David A. Kukla, Tatiana Sharapova, Rita Ciurlionis, Terry Van Vleet, Jill M. Wetter, Vincent C. Peterkin, Anthony J. Lee, Kennan C. Marsh, Yueting Wang, Prathap Kumar S. Mahalingaiah et al. · 2025 · Toxicological Sciences
  65. A genomic-led strategy to anticipate drug safety effects
    Brian R. Ferolito, Andréa R. V. R. Horimoto, Kai Gravel-Pucillo, Daniel J Golden, Hesam Dashti, Claudia Giambartolomei, Danielle Rasooly, Rachael Matty, Liam Gaziano, Yakov A. Tsepilov et al. · 2026 · PLoS Genetics
  66. Functionalized drug delivery systems: regulatory considerations
    Ayush Gupta, Amit Kumar, Awesh Kumar Yadav · 2025 · Elsevier eBooks
  67. Tümör-Bağışıklık Hücre Etkileşimlerini Araştırmak İçin Biyomühendisliksel Yöntemler
    Tuğba Topal, Zehra Ece Uzun · 2025 · Gazi Üniversitesi Fen Fakültesi Dergisi
  68. Development of a liquid overlay-based three-dimensional cell culture panel for drug screening applications
    Marie Depresle, Pierre Daumar, Antoine Goisnard, Manon Roux, Corinne Aubel, Frederique Madeleine Penault-Llorca, Emmanuelle Mounetou, Mahchid Bamdad · 2025 · Scientific Reports
  69. Preregistration in Animal Experimentation – A Qualitative Study on Researchers’ Views in Switzerland
    Cristina Priboi, Simone Lalor, Giorgia Sarra, Evie Vergauwe, Bernice S. Elger, Hanno Würbel · 2025 · Research Square
  70. Additional file 3 of Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer
    Espedal, Heidi, Berg, Hege F., Fonnes, Tina · 2021 · Figshare
  71. Additional file 2 of Feasibility and utility of MRI and dynamic 18F-FDG-PET in an orthotopic organoid-based patient-derived mouse model of endometrial cancer
    Espedal, Heidi, Berg, Hege F., Fonnes, Tina · 2021 · Figshare
  72. The organ-on-a-chip mirage: Animal replacement, plastic channels, and plastic claims: The False Narrative Behind the War on Animal Research
    Martin L Yarmush · 2025 · Innovation and Emerging Technologies
  73. 3D-Cell Culture Systems: Current State
    I. A. Ivashchenko, Walentin Wasielewski, O. S. Fedotova, В. Н. Слаутин, А.V. Semenov · 2025 · Applied Biochemistry and Microbiology
  74. TriCloud: Drug-Target-Disease Ternary Network for Drug Repositioning Research Based on Point Cloud Modeling
    Xiwei Tang, Wanjun Ma, Anzheng Gao · 2026 · IEEE Transactions on Computational Biology and Bioinformatics
  75. Glycovecteurs pour le ciblage thérapeutique d'une maladie rare lysosomale : la maladie de Pompe
    Afitz Da Silva · 2017
  76. Immunothérapie du cancer par administration d’anticorps monoclonaux anti-HVEM ou anti-ICOS chez la souris humanisée : potentiel thérapeutique et effets immunologiques
    Simon Brunel · 2017 · theses.fr (ABES)
  77. Développement d’un concept innovant de détection et de quantification de la protéine « Multidrug Resistance » P-gp avec les traceurs fluorescents LightSpot® ainsi que d’une nouvelle méthodologie de conservation de sphéroïdes du cancer du sein Triple Négatif dans le milieu synthétique OptiPASS®
    Antoine Goisnard · 2021
  78. Évaluation de la perméabilité cellulaire de formulations médicamenteuses au travers de membranes d’émulsions adhésives biomimétiques
    Vincent Faugeras · 2021
  79. Therapeutic targets for cardiovascular diseases
    Basant Kumar, Sujata Saini · 2026 · Elsevier eBooks
  80. Computational Intelligence for Drug Design and Development
    Kritika Shukla, Hina Bansal · 2026 · Advances in computational intelligence and robotics book series
  81. A call for preregistration of in vitro research
    Céline Heinl, Nuno Henrique Franco, Bettina Bert, Katherina Siewert, Dania Movia, Edlira Aruçi, Carina Ladeira, Ahmed Y. Sanin, Winfried Neuhaus, Ulf D. Kahlert et al. · 2026 · EMBO Reports
  82. Definitions, Principles, and Concepts of Pharmacoepidemiology and Pharmacovigilance
    Tichawona Chinzowu, Prasad S. Nishtala · 2026 · Elsevier eBooks
  83. Lineage-specific lncRNAs critically determine cross-species differences in tumors
    Jie Lin, Xiuying Liu, Hao Zhu · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  84. Druggable Genome-Wide Mendelian Randomization Identifies Therapeutic Targets and DNA Methylation-Mediated Regulation in Urological Malignancies
    Taoen Li, Qiang Wei · 2026 · Technology in Cancer Research & Treatment
  85. High-Throughput Complex Disease Modeling for Ethical Drug Discovery: Clinical Relevance of a NAM Platform for Cancer Biomarker Development
    Emma Dillier, Sousa Raquel, Kluser Tanja, O. Schicht, P. Leu Marco, Faisst Arne-C. · 2026 · Journal of Cancer Genetics and Biomarkers
  86. Refining drug screening with automated home cage monitoring: a crossover study in socially housed rats
    David A. Connor, Brady Nifong, Jason D. Payseur, Xuejun Wu, Eric I. Rossman, Ajeesh Koshy Cherian · 2026 · Frontiers in Toxicology
  87. Integrated Screening Cascades for Ion-Channel Drug Discovery: Linking Structure, Electrophysiology, Safety Pharmacology, and Human-Relevant Models
    Yohan Seo · 2026 · International Journal of Molecular Sciences
  88. Physical feasibility gating in early drug discovery: a decision framework for identifying predictable physical failures, with retrospective illustration
    Sarfaraz K. Niazi · 2026 · Frontiers in Drug Discovery
  89. Vascularization in Biofabrication: Innovative Strategies for Advanced Tissue Models
    Yvonne Kulicke, Rafael Schmid, Theresa Promny, Tannaz Karimi, Evelin Sandor, Lisa Wedler, Celena A. Sörgel, Andreas Arkudas, Annika Kengelbach‐Weigand, Raymund E. Horch · 2026 · Cells
  90. AI-driven Approaches for Target Discovery in Drug Design
    Hiroaki Iwata · 2026 · Royal Society of Chemistry eBooks
  91. PIP3 antagonist as a molecular regulator in MSC-derived cardiomyocytes: Potential in vitro therapeutic implications for conotruncal heart defects
    Alaaeldin G. Fayez, Nora N. Esmaiel, Haiam Abdel Raouf, Mohamad M. Aboelenin, Riham Mohammed Aly, Ghada Nour Eldeen · 2026 · Journal of Genetic Engineering and Biotechnology
  92. Applications in Modern Research
    Simone Badal · 2026 · Springer eBooks
  93. An immunocompetent transplantable mouse model of basal cell carcinoma
    Martin Wiinberg, Kristian Kåber Pedersen, Catharina Margrethe Lerche · 2026 · JID Innovations
  94. Flow-dependent drug response of breast Cancer organoids in an organ-on-Chip platform
    Ece Kocamaz, Deren Aslan, Veli Özbolat, Tolga Köşeci, Çetin Canpolat · 2026 · Microchemical Journal
  95. Ion channels as emerging drug targets: Pharmacological insights and therapeutic advances
    Anand B. Mundada, Pooja Anand Mundada, S. Kathirvel, P. Ram Kumar, P. Krishnamoorthy, Nouhaila Ezzaoui, Mayank Sharma, Aayush Sharma, Sohom Mukherjee, E. Joel Mart et al. · 2026 · Current Proteomics
  96. Integration of microphysiological systems with computational and digital twin modeling for pharmaceutical development: a systematic review
    Marzieh Soheili, Behdad Gilzad Kohan, Leila Rastegar, Yousef Moradi, Hamed Gilzad Kohan · 2026 · Journal of Pharmacy & Pharmaceutical Sciences
  97. Decision-focused discovery toxicology: Why early, human-relevant risk assessment of new drugs gives a competitive advantage
    Yvonne Will, Lindsey J. Talecki, Ruth Angela Roberts · 2026 · Current Opinion in Toxicology